一项比较 Ferumoxytol 与铁蔗糖治疗慢性肾脏病成人受试者缺铁性贫血的试验 (FIRST)
2023年7月18日 更新者:AMAG Pharmaceuticals, Inc.
Ferumoxytol 与铁蔗糖试验(FIRST)的比较:一项随机、多中心的试验,Ferumoxytol 与铁蔗糖相比,用于治疗成人慢性肾脏病患者的缺铁性贫血
该研究的目的是评估静脉注射 (IV) ferumoxytol 与静脉注射铁蔗糖相比治疗慢性肾脏病 (CKD) 患者缺铁性贫血 (IDA) 的安全性和有效性。
研究概览
研究类型
介入性
注册 (实际的)
162
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Ontario
-
Richmond Hill、Ontario、加拿大
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Quebec
-
Montréal、Quebec、加拿大、H3A 1A1
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Montréal、Quebec、加拿大、H4J 1C5
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Bangalore、印度
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Nagpur、印度
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Pune、印度
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Berlin、德国
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Düsseldorf、德国
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Göttingen、德国
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Munich、德国
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Nürnberg、德国
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Passau、德国
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Antwerpen、比利时、2020
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Antwerpen、比利时、2060
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Katowice、波兰
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Opole、波兰
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Radom、波兰
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Szczecin、波兰
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Warszawa、波兰
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Łódź、波兰
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
Arizona
-
Tempe、Arizona、美国、85284
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
California
-
Chula Vista、California、美国、91910
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Mountain View、California、美国、94041
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Whittier、California、美国、90602
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Georgia
-
Augusta、Georgia、美国、30901
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Idaho
-
Meridian、Idaho、美国、83642
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Illinois
-
Evergreen Park、Illinois、美国、60805
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Louisiana
-
Shreveport、Louisiana、美国、71101
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Maryland
-
Bethesda、Maryland、美国
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Massachusetts
-
Springfield、Massachusetts、美国、01107
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New York
-
Flushing、New York、美国、11355
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Rosedale、New York、美国
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Pennsylvania
-
Bethlehem、Pennsylvania、美国、18017
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Texas
-
San Antonio、Texas、美国、78229
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
London、英国
- For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
描述
纳入标准:
主要纳入标准包括:
- ≥18岁的男性和女性
- 估计肾小球滤过率 <60 mL/min 或 CKD 诊断(如肾病、肾炎)
- 血红蛋白 <11.0 克/分升 (dL)
- 转铁蛋白饱和度<30%
- 血液透析参与者在筛选前接受至少 3 个月的维持性透析,目前每周接受 3 次透析
- 具有生育潜力且性活跃的女性参与者必须在筛选前至少 1 个月采用有效的节育方法,并同意在研究完成前继续节育
排除标准:
主要排除标准包括:
- IV 铁过敏史
- 对 2 类或更多类药物过敏
- 已怀孕或打算怀孕、哺乳、产后3个月内或血清或尿液妊娠试验阳性的女性参与者
- 血红蛋白≤7.0 g/dL
- 在筛选前 4 周内接受过另一种研究药物,或计划在研究期间接受过未指定的研究药物
- 除缺铁以外的已知贫血原因(如溶血和维生素 B12 或叶酸缺乏)
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:铁氧醇
参与者在第 1 天(基线)接受了 ferumoxytol(510 毫克 [mg]、17 毫升 [mL])的静脉注射。
随后在 5±3 天后第二次注射 ferumoxytol(510 mg,17 mL),总累积剂量为 1.02 克(g)。
|
IV Ferumoxytol
其他名称:
|
有源比较器:蔗糖铁
参与者根据血液透析状态接受蔗糖铁。 血液透析参与者在第 1 天(基线)和随后的 9 次连续血液透析疗程中接受缓慢静脉注射或静脉滴注 100 毫克蔗糖铁,总累积剂量为 1.0 克。 未进行透析的参与者在第 1 天(基线)接受缓慢静脉注射或静脉滴注 200 mg 蔗糖铁,并在 14 天内的非连续日进行 4 次后续就诊,总累积剂量为 1.0 g。 |
IV 铁蔗糖
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
从基线(第 1 天)到第 5 周的血红蛋白平均变化
大体时间:基线(第 1 天),第 5 周
|
每个参与者的血红蛋白从基线(第 1 天)到第 5 周的变化计算如下: 血红蛋白变化 = 血红蛋白(第 5 周)- 血红蛋白(基线) 带有标准误差的最小二乘平均值报告为克/分升 (dL)。 每个参与者的基线血红蛋白是第 1 天的血红蛋白值(注射研究药物之前)。 筛选血红蛋白值用于缺少基线(第 1 天)血红蛋白的任何参与者。 分析使用最后观察到的结转 (LOCF) 插补方法来计算 ITT 群体的缺失值。 敏感性分析是在没有对缺失数据进行填补的情况下使用马尔可夫链蒙特卡罗方法进行的。 |
基线(第 1 天),第 5 周
|
从第 1 天(基线)到第 5 周血红蛋白增加≥1.0 g/dL 的参与者百分比
大体时间:基线(第 1 天)到第 5 周
|
治疗组从基线(第 1 天)到第 5 周的任何时间血红蛋白增加 ≥ 1.0 g/dL 的参与者百分比按研究访视显示。
每个参与者的基线血红蛋白是第 1 天的血红蛋白值(注射研究药物之前)。
|
基线(第 1 天)到第 5 周
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014 Jun;89(6):646-50. doi: 10.1002/ajh.23712.
- Strauss WE, Dahl NV, Li Z, Lau G, Allen LF. Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. BMC Hematol. 2016 Jul 26;16:20. doi: 10.1186/s12878-016-0060-x. eCollection 2016.
- Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12. doi: 10.2215/CJN.05320513. Epub 2014 Jan 23.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2010年3月1日
初级完成 (实际的)
2011年7月19日
研究完成 (实际的)
2012年4月19日
研究注册日期
首次提交
2010年1月15日
首先提交符合 QC 标准的
2010年1月19日
首次发布 (估计的)
2010年1月20日
研究记录更新
最后更新发布 (实际的)
2023年7月25日
上次提交的符合 QC 标准的更新
2023年7月18日
最后验证
2023年7月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- FER-CKD-201
- 2009-015630-30 (EudraCT编号)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
铁氧醇的临床试验
-
Sunnybrook Health Sciences CentreUnity Health Toronto完全的
-
Massachusetts General HospitalNational Cancer Institute (NCI)完全的